Arthur G. Palmer and Oliver Hobert of the Department of Biochemistry & Molecular Biophysics were selected in recognition of their distinguished and continuing achievements in research.
A study co-led by Columbia scientists suggests a nutrient transporter located at the blood-brain barrier could be commandeered to sneak therapeutic drugs into the brain.
Columbia researchers have found that cells inside clogged arteries have cancer-like properties that aggravate atherosclerosis, and anticancer drugs could be a new treatment.
Smell’s sensory magic emerges from an intricate developmental mechanism that tailors each of the nose’s sensory cells to detect a specific odor chemical.
Sara Zaccara took a risk as a postdoc when she jumped into the new field of epitranscriptomics, but her discoveries have paid off and are now being tested in patients.
A new study is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development of new treatments.
An expanding artificial heart valve being developed by Columbia surgeons and engineers could simplify treatment for many kids born with congenital heart disease.
Columbia researchers discovered stem cells in mice that are essential in maintaining healthy cartilage inside joints, but the cells go missing with age or after injury.
Many Black Americans thought to have a high risk of developing kidney disease possess a genetic variant that eradicates the extra risk, a new study from Columbia researchers has found.
Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
Columbia physicians and patients were essential in demonstrating the effectiveness of the world’s first CRISPR gene-editing therapy, now approved for use in the United States.
Columbia, Yale, and CHLA researchers have found that brain connectivity is different in infants born to mothers who felt stress from discrimination and acculturation while pregnant.
A pilot feasibility study to assess a new therapy addresses a critical gap in treatment options for a high-risk patient population with unique emotional needs.